What Is Akebia Therapeutics, Inc. (AKBA) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Akebia Therapeutics, Inc.'s intrinsic value is estimated at $1.36, presenting a divided outlook at the current price of $1.38. With an average implied return of -1.1% across a split 6–5 (bull–bear) consensus, the model spread of +299.4% underscores analytical uncertainty. Notably, RCMH-DCF sees the most upside at +205.7% (fair value: $4.22), while First Chicago is the most conservative at -93.7% ($0.09). The spread between these extremes — +299.4% — reveals how different analytical frameworks can reach starkly different conclusions.
What Do the Models Say About AKBA?
12 of 13 models are currently active for AKBA. Of these, 7 models suggest upside while 5 models suggest overvaluation. The Bayesian DCF estimates AKBA's intrinsic value at $0.77, implying -44.2% downside from the current price. See which stocks rank higher →
How Does AKBA Rank in Drug Manufacturers - Specialty & Generic?
Among 13 Drug Manufacturers - Specialty & Generic stocks, AKBA ranks #8 by Quality of Company score. CirclFi's QOC score of 5.8/10 evaluates 32 fundamental signals. A score of 5.8 reflects mixed fundamentals.
Within the Drug Manufacturers - Specialty & Generic space, Akebia Therapeutics, Inc. competes in an environment where R&D productivity ratio often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.
Is AKBA a Value Trap?
CirclFi's Value Trap algorithm assigns AKBA a score of 43/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
12 of 13 models are active for Akebia Therapeutics, Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, Akebia Therapeutics, Inc. is rated at 5.8/10. This solid-tier score maintains reasonable quality metrics with some areas for improvement.
The gap between the most bullish and bearish model spans +299.4% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every AKBA valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across AKBA's 12 active models, average confidence is 33%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad